SlideShare uma empresa Scribd logo
1 de 38
Baixar para ler offline
Radiologie Interventionnelle
&
CHC
Thierry de Baère
Imagerie thérapeutique - Gustave Roussy - Villejuif
Journée d’Hépatologie du Centre Hépato-Biliaire
12 juin 2015 - Paris
J Hepatol 2012. 56; 908–943. JM. Llovet; R Lencioni; AM. Di Bisceglie; PR. Galle; JF Dufour; TF. Greten; E
Raymond; T Roskams; T de Baere; Michel Ducreux; and Vincenzo Mazzaferro.
J Hepatol 2012. 56; 908–943. JM. Llovet; R Lencioni; AM. Di Bisceglie; PR. Galle; JF Dufour; TF. Greten; E
Raymond; T Roskams; T De Baere; Michel Ducreux; and Vincenzo Mazzaferro.
%
AP
n=928
EU
n=1113
LA
n=90
USA
n=563
Japan
n=508
Overall
N=3202
All LRTs 67.2 43.5 27.8 49.4 84.4 57.5
TACE 60.3 33.1 13.3 37.1 71.3 47.2
Conventional
Lipiodol TACE * 90.2 59.2 83.3 40.7 82.3 73.9
DEB-TACE *
2.9 36.1 16.7 39.7 1.7 15.9
Ablation 15.5 20.2 17.8 12.6 50.0 22.2
Surgery 24.2 15.5 5.6 9.4 43.3 21.1
* For patients who received TACE: n=1511; AP=560, EU=368, LA=12, USA=209, Japan=362;
AP, Asia-Pacific; LA, Latin America; LRTs, Loco-Regional Therapies
Lencioni R et al. Int J Clin Pract 2014;68:609-617
GIDEON
Pre-Sorafenib therapy in 3202 HCC (observation)
Breen DJ,. Nat Rev Clin Oncol 2015;12:175-186
Ablation for Early-Stage HCC:
Italy
Japan
Corea
France
Feng K et al. J Hepatol 2012;57:794-802Huang J et al. Ann Surg 2010;252:903-912
● 230 patients, 94% Child A
● Single ≤ 5 cm, up to 3 ≤ 3 cm
● 168 patients, 49% Child A
● Up to 2 HCC tumors ≤ 4 cm
Overall Survival Overall Survival
months months
p = 0.001 (log-rank test) p = 0.342 (log-rank test)
Ablation vs. Resection : Randomized Trials
Feng K et al. J Hepatol 2012;57:794-802Huang J et al. Ann Surg 2010;252:903-912
● 230 patients, 94% Child A
● Single ≤ 5 cm, up to 3 ≤ 3 cm
● 168 patients, 49% Child A
● Up to 2 HCC tumors ≤ 4 cm
Overall Survival Overall Survival
months months
p = 0.001 (log-rank test) p = 0.342 (log-rank test)
Ablation vs. Resection : Randomized Trials
"Very Early” (stage 0) vs "Early" (stage A) VS “Milan”
Sasaki A et al. Cancer 2005;103:299-306
46% of patients
with single HCC
< 5 cm show
microsatellites
on histology
Radiofrequency ablation is recommended in most instances as the main ablative therapy in
tumours less than 5 cm due to a significantly better control of the disease
(evidence 1iD; recommendation 1A)
J Hepatol 2012. 56; 908–943. JM. Llovet; R Lencioni; AM. Di Bisceglie; PR. Galle; JF Dufour; TF. Greten; E
Raymond; T Roskams; T de Baere; Michel Ducreux; and Vincenzo Mazzaferro.
Milan criteria : X3 <3cm ; >5cm
Pompili M et al. J Hepatol 2013;59:89-97
Tumor Recurrence
Overall Survival
Ablation in HCC : APASL Consensus
Omata M et al. Hepatol Int 2010;4:439-474
LOCATION!
T
Omata M et al. Hepatol Int 2010;4:439-474
Ablation in HCC : APASL Consensus
Forner et al. Lancet 2012;379:1245-1255
Ablation Ablation
The Two Roles of Ablation in HCC Treatment:
Updated BCLC Treatment Algorithm
Focused Ultrasound Cryoablation
Radiofrequency Ablation
Irreversible Electroporation
Laser AblationMicrowave Ablation
Mazzaferro V, Lencioni R, Majno P. Semin Liver Dis 2014;34:415-426
Image-Guided Ablation of HCC:
Evolving Methods and Technologies
• Resection et ablation sont probablement équivalente pour
les stade 0 et A (very early; early)
 Complémentaire plus que compétitive : localisation
• Pour les HCC < 5cm si candidat chirurgicaux limites
 Rôle des nouvelles techniques d’ablation à définir , outil par outil
 Traitement combiné (TACE+RF)
• La difficultés est plus celle de la récidive à distance que de
la récidive locale
 Traitement préventif ! (STORM study)
Ablation for Early-Stage HCC
BCLC Staging and Treatment Strategy:
Critical Considerations
EASL-EORTC. J Hepatol 2012;56:908-943 - Eur J Cancer 2012;48:599-641
BCLC Staging and Treatment Strategy:
Critical Considerations
EASL-EORTC. J Hepatol 2012;56:908-943 - Eur J Cancer 2012;48:599-641
ADVANCED STAGE:
- ECOG PS 1-2
- Portal Vein Invasion
- Extrahepatic Disease
(Yau T. Gastroenterology 2014;146:1691–1700 )EVM : extrahe-patic or vascular invasion/metastasis
0 / 1 / 2 negative factor
Tumor size: ≥ 5 cm
Tumor number: ≥ 3
Intrahepatic vascular invasion
(Yau T. Gastroenterology 2014;146:1691–1700 )
• HKC identified subsets of BCLC B & 50% of BCLCC C
more aggressive treatments than recommended by BCLC
Such aggressive treatments Improved survival outcomes
 hypothetical median OS: HKLC 16.6 months, BCLC 8.9 months)
“The benefits of the HKLC system are clearly apparent when dealing with
patients who have intermediate to advanced stage disease according to
the BCLC”.
“In a European cohort of HCC patients, the newly developed HKLC staging
system does not seem to allow a better predictive value than the BCLC”.
(Adhoute X. J Hepatol 2014)
(Chapiro J. Nat Rev Gastroenterol Hepatol 2014;11:334-336)
177 patients randomized to DEB-TACE or c-TACE (med number of TACE = 2)
• 89 DEB-TACE
• 88 cTACE
(Golfieri R. 2014 BJC; 111 : 255–264)
CR
OR
DC
Targeted Overall
(Golfieri R. 2014 BJC; 111 : 255–264)
(Golfieri R. 2014 BJC; 111 : 255–264)
• Median TTP = 9 months in both arms
• 1- and 2-year survival
 86.2% and 56.8% after DEB-TACE
 83.5% and 55.4% after cTACE (p=0.949).
No difference in AE incidence and severity
except post-TACE pain, more frequent and severe after cTACE (p=0.001).
Pain did not affected the length of hospital stay and patient acceptance of
additional TACEs
(Golfieri R. 2014 BJC; 111 : 255–264)
Radiologieinterventionnellechctdebaere
67 DEB-TACE (53 patients) 100-300 μm (Group 1)
lobar in 42 and selective in 7 cases
65 DEB-TACE (54 patients) 70-150 μm (Group 2)
lobar in 60 and selective in 11
m-RECIST
1-2 months
CR
(%)
PR
(%)
SD
(%)
PD
(%)
Group 1 19 2 67 12
Group 2 16 8 69 7
(Deipolyi AR, J Vasc Interv Radiol 2015; 26:516–522)
BCLC Staging and Treatment Strategy:
Critical Considerations
EASL-EORTC. J Hepatol 2012;56:908-943 - Eur J Cancer 2012;48:599-641
Radioembolization
- Sarra
- Soramic
- STOPP HCC
A single-centre prospective study of 291 patients with HCC looked
at long-term clinical outcomes with TheraSphere®
Overall response rate according to WHO criteria was 42%
TheraSphere® & HCC
29
Treatment response predicts survival benefit for BCLC A, B &C patients
Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of
long-term outcomes. Gastroenterology 2010;138(1):52–64.
(Garlipp B, de Baere T, Seidensticker M. Hepatology 2014.59:1864-1873)
26 matched pairs
PVE : 61.5 ± 39 % after 33 [24-56] days
RE : 29 ± 28 % after 46 [27-79] days (p<0.001)
Traitements combinés
(Peng ZW; JCO 2013. 31 426-432)
HCC less than 7 cm (single), or X3 & <3cm
TACE-RFA Vs RFA
OS : (HR=0.525; 95% CI = 0.335-0.822; P = .002 )
DFS : (HR=0.575; 95% CI = 0.374-0.897; P = .009)
OS :
treatment allocation (HR=1.87), tum. Size 3cm (HR=1.73),
and tum. number (HR=2.49)
DFS :
Treatment allocation (HR=1.67) and tum. Number (HR=1.97)
HR: 0.797
95% Cl: 0.588, 1.08
P = 0.072
Sorafenib
Median: 169 days
95% Cl: 166, 219 days
Placebo
Median: 166 days
95% Cl: 113, 168 days
PrimaryEndpoint Sorafenib 400mg bid
Matching Placebo
R
A
N
D
O
M
I
Z
E
1 3 5 7 9 11 13 15 17 19
TACE
(optional)
Cycle no
(=4 weeks)
n=154
n=153
SPACE Trial
PRODIGE 16 - ESSAI FFCD 0905
ESSAI RANDOMISE EN DOUBLE AVEUGLE DE PHASE II-III EVALUANT LA
CHIMIOEMBOLISATION COMBINEE AU SUNITINIB OU A UN PLACEBO CHEZ DES
PATIENTS ATTEINTS DE CARCINOME HEPATOCELLULAIRE (SATURNE)
DEB - TACE with sunitinib 37.5 mg/d orally 4 weeks out of 6 started 7-15 days before TACE for one year vs placebo.
Primary end-point : specific safety of the TACE-sunitinib combination (severe bleeding, liver failure , …)
Secondary end-points : general safety, progression-free survival (PFS), Overall Survival (OS), quality of life.
May 2011 to May 2014 : 78 patients were randomized (39 in each arm)
median age 66 years [IQR (60-70)]. Bilobar HCC : 41 / 70 patients
The median number of cycles was 3 [IQR : 2 :5 ] in arm A and 5 [IQR : 4 :7 ] in arm B
.No bleeding complication; 1liver failure (PT = 40%) armA, & 2 liver failure in arm B (PT=42%, ,encephalopathy).
Sunitinib dose was reduced to 25 mg/d as a result of toxicity for 19 pts (48.7%) in arm A. 6 patients are still under treatment
(3 in each arm). The main grades 3-4 toxicities were: thrombocytopenia (28.2% vs. 2.6% in placebo arm), neutropenia
(28.2% vs. none), asthenia (20.5% vs. 5.3%), diarrhea (5.1% vs. none) respectively in arm A and B. The median PFS in arm
A was 8.8 [95%CI 5.8 -12] months, and 6.3 [95%CI 4.2 - 9.0 ] months in arm B.
Conclusion
This study indicated a modest and manageable toxicity of sunitinib when combined with TACE. Regarding efficacy endpoints
(PFS and OS) we are waiting for more mature data as 6 patients are still under treatment.
RFA plus Sorafenib vs RFA Alone in RCC
Hakimé et al, Radiology 2007
4-time increase in ablation volume
125 HCC received TACE
group A (n = 61) : TACE + As2O3 at 10 mg/d for 4 courses (21 days per course)
group B (n = 64) : TACE alone
125 HCC received TACE
group A (n = 61) : TACE + As2O3 at 10 mg/d for 4 courses (21 days per course)
group B (n = 64) : TACE alone
J Vasc Interv Radiol 2014; 25:379–387
%
EU
n=1113
Overall
N=3202
All LRTs 43.5 57.5
TACE 33.1 47.2
Conventional
Lipiodol TACE * 59.2 73.9
DEB-TACE *
36.1 15.9
Ablation 20.2 22.2
Surgery 15.5 21.1
Conclusion
DOSISPHERES-01
Y-90 GLASS MICROSPHERES FOR HCC :OPTIMIZED DOSIMETRY vs STANDARD DOSIMETRY
STOPP HCC
Y-90 GLASS MICROSPHERES FOR HCC PRIOR TO SORAFENIB THERAPY vs STANDARD DOSIMETRY
Sunitinib loaded beads
Lipiodol ready to inject emulsion

Mais conteúdo relacionado

Mais procurados

How to predict po course before and during surgery for HCC
How to predict po course before and during surgery for HCCHow to predict po course before and during surgery for HCC
How to predict po course before and during surgery for HCCEric Vibert, MD, PhD
 
Liver Transplantation in the setting of HIV infection
Liver Transplantation in the setting of HIV infectionLiver Transplantation in the setting of HIV infection
Liver Transplantation in the setting of HIV infectionEric Vibert, MD, PhD
 
Liver transplantation vs Resection in cholangiocarcinoma on cirrhosis
Liver transplantation vs Resection in cholangiocarcinoma on cirrhosisLiver transplantation vs Resection in cholangiocarcinoma on cirrhosis
Liver transplantation vs Resection in cholangiocarcinoma on cirrhosisEric Vibert, MD, PhD
 
Liver Transplantation for Cholangiocarcinoma
Liver Transplantation for CholangiocarcinomaLiver Transplantation for Cholangiocarcinoma
Liver Transplantation for CholangiocarcinomaEric Vibert, MD, PhD
 
Innovations in liver surgery for Hepatocellular Carcinoma
Innovations in liver surgery for Hepatocellular CarcinomaInnovations in liver surgery for Hepatocellular Carcinoma
Innovations in liver surgery for Hepatocellular CarcinomaEric Vibert, MD, PhD
 
Liver Transplantation with severe steatotic graft and postoperative organ dys...
Liver Transplantation with severe steatotic graft and postoperative organ dys...Liver Transplantation with severe steatotic graft and postoperative organ dys...
Liver Transplantation with severe steatotic graft and postoperative organ dys...Eric Vibert, MD, PhD
 
Traitement Chirurgical HCC Conf Zurich
Traitement Chirurgical HCC Conf ZurichTraitement Chirurgical HCC Conf Zurich
Traitement Chirurgical HCC Conf ZurichEric Vibert, MD, PhD
 
Arterial Lactate Concentration is a major pronostic factor after elective sur...
Arterial Lactate Concentration is a major pronostic factor after elective sur...Arterial Lactate Concentration is a major pronostic factor after elective sur...
Arterial Lactate Concentration is a major pronostic factor after elective sur...Eric Vibert, MD, PhD
 
Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015
Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015
Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015Eric Vibert, MD, PhD
 
Dalle linee guida dell'epatocarcinoma alla pratica clinica - Gastrolearning®
Dalle linee guida dell'epatocarcinoma alla pratica clinica - Gastrolearning®Dalle linee guida dell'epatocarcinoma alla pratica clinica - Gastrolearning®
Dalle linee guida dell'epatocarcinoma alla pratica clinica - Gastrolearning®Gastrolearning
 
Costo efficacia della terapia con sorafenib nel trattamento dell’HCC - Gastro...
Costo efficacia della terapia con sorafenib nel trattamento dell’HCC - Gastro...Costo efficacia della terapia con sorafenib nel trattamento dell’HCC - Gastro...
Costo efficacia della terapia con sorafenib nel trattamento dell’HCC - Gastro...Gastrolearning
 
La terapia chirurgica del cancro del pancreas - Gastrolearning®
La terapia chirurgica del cancro del pancreas - Gastrolearning®La terapia chirurgica del cancro del pancreas - Gastrolearning®
La terapia chirurgica del cancro del pancreas - Gastrolearning®Gastrolearning
 
Epatocarcinoma: nulla di nuovo sotto il sole - Gastrolearning®
Epatocarcinoma: nulla di nuovo sotto il sole -  Gastrolearning®Epatocarcinoma: nulla di nuovo sotto il sole -  Gastrolearning®
Epatocarcinoma: nulla di nuovo sotto il sole - Gastrolearning®Gastrolearning
 
Lesioni cistiche pancreatiche: linee guida diagnostiche - Gastrolearning®
Lesioni cistiche pancreatiche: linee guida diagnostiche - Gastrolearning®Lesioni cistiche pancreatiche: linee guida diagnostiche - Gastrolearning®
Lesioni cistiche pancreatiche: linee guida diagnostiche - Gastrolearning®Gastrolearning
 
Radiological evaluation aasld 2011
Radiological evaluation aasld 2011Radiological evaluation aasld 2011
Radiological evaluation aasld 2011mbouattour
 

Mais procurados (20)

How to predict po course before and during surgery for HCC
How to predict po course before and during surgery for HCCHow to predict po course before and during surgery for HCC
How to predict po course before and during surgery for HCC
 
Liver Transplantation in the setting of HIV infection
Liver Transplantation in the setting of HIV infectionLiver Transplantation in the setting of HIV infection
Liver Transplantation in the setting of HIV infection
 
Liver transplantation vs Resection in cholangiocarcinoma on cirrhosis
Liver transplantation vs Resection in cholangiocarcinoma on cirrhosisLiver transplantation vs Resection in cholangiocarcinoma on cirrhosis
Liver transplantation vs Resection in cholangiocarcinoma on cirrhosis
 
Liver Transplantation for Cholangiocarcinoma
Liver Transplantation for CholangiocarcinomaLiver Transplantation for Cholangiocarcinoma
Liver Transplantation for Cholangiocarcinoma
 
Innovations in liver surgery for Hepatocellular Carcinoma
Innovations in liver surgery for Hepatocellular CarcinomaInnovations in liver surgery for Hepatocellular Carcinoma
Innovations in liver surgery for Hepatocellular Carcinoma
 
Moreau r betabloquants_non_selectifs_et_cirrhose_hepatique_fev2015
Moreau r betabloquants_non_selectifs_et_cirrhose_hepatique_fev2015Moreau r betabloquants_non_selectifs_et_cirrhose_hepatique_fev2015
Moreau r betabloquants_non_selectifs_et_cirrhose_hepatique_fev2015
 
Liver Transplantation with severe steatotic graft and postoperative organ dys...
Liver Transplantation with severe steatotic graft and postoperative organ dys...Liver Transplantation with severe steatotic graft and postoperative organ dys...
Liver Transplantation with severe steatotic graft and postoperative organ dys...
 
Nouvellesapprochestherapeutiqueshepatitebmlevrero
NouvellesapprochestherapeutiqueshepatitebmlevreroNouvellesapprochestherapeutiqueshepatitebmlevrero
Nouvellesapprochestherapeutiqueshepatitebmlevrero
 
Traitement Chirurgical HCC Conf Zurich
Traitement Chirurgical HCC Conf ZurichTraitement Chirurgical HCC Conf Zurich
Traitement Chirurgical HCC Conf Zurich
 
Chirurgie ouverte ou laparoscopique du foie : comment définir les limites ? -...
Chirurgie ouverte ou laparoscopique du foie : comment définir les limites ? -...Chirurgie ouverte ou laparoscopique du foie : comment définir les limites ? -...
Chirurgie ouverte ou laparoscopique du foie : comment définir les limites ? -...
 
Arterial Lactate Concentration is a major pronostic factor after elective sur...
Arterial Lactate Concentration is a major pronostic factor after elective sur...Arterial Lactate Concentration is a major pronostic factor after elective sur...
Arterial Lactate Concentration is a major pronostic factor after elective sur...
 
Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015
Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015
Surgery at the Borderline in HCC patient - EASL Conference - Vienna 2015
 
Resection early hcc
Resection early hccResection early hcc
Resection early hcc
 
Innovation in Liver Surgery
Innovation in Liver SurgeryInnovation in Liver Surgery
Innovation in Liver Surgery
 
Dalle linee guida dell'epatocarcinoma alla pratica clinica - Gastrolearning®
Dalle linee guida dell'epatocarcinoma alla pratica clinica - Gastrolearning®Dalle linee guida dell'epatocarcinoma alla pratica clinica - Gastrolearning®
Dalle linee guida dell'epatocarcinoma alla pratica clinica - Gastrolearning®
 
Costo efficacia della terapia con sorafenib nel trattamento dell’HCC - Gastro...
Costo efficacia della terapia con sorafenib nel trattamento dell’HCC - Gastro...Costo efficacia della terapia con sorafenib nel trattamento dell’HCC - Gastro...
Costo efficacia della terapia con sorafenib nel trattamento dell’HCC - Gastro...
 
La terapia chirurgica del cancro del pancreas - Gastrolearning®
La terapia chirurgica del cancro del pancreas - Gastrolearning®La terapia chirurgica del cancro del pancreas - Gastrolearning®
La terapia chirurgica del cancro del pancreas - Gastrolearning®
 
Epatocarcinoma: nulla di nuovo sotto il sole - Gastrolearning®
Epatocarcinoma: nulla di nuovo sotto il sole -  Gastrolearning®Epatocarcinoma: nulla di nuovo sotto il sole -  Gastrolearning®
Epatocarcinoma: nulla di nuovo sotto il sole - Gastrolearning®
 
Lesioni cistiche pancreatiche: linee guida diagnostiche - Gastrolearning®
Lesioni cistiche pancreatiche: linee guida diagnostiche - Gastrolearning®Lesioni cistiche pancreatiche: linee guida diagnostiche - Gastrolearning®
Lesioni cistiche pancreatiche: linee guida diagnostiche - Gastrolearning®
 
Radiological evaluation aasld 2011
Radiological evaluation aasld 2011Radiological evaluation aasld 2011
Radiological evaluation aasld 2011
 

Destaque

Destaque (20)

Hepatitecnouveauxantivirauxetinteractionsmedicamenteusesgpeytavin
HepatitecnouveauxantivirauxetinteractionsmedicamenteusesgpeytavinHepatitecnouveauxantivirauxetinteractionsmedicamenteusesgpeytavin
Hepatitecnouveauxantivirauxetinteractionsmedicamenteusesgpeytavin
 
Quelleplacedelatepdanschcmacastilla
QuelleplacedelatepdanschcmacastillaQuelleplacedelatepdanschcmacastilla
Quelleplacedelatepdanschcmacastilla
 
Quandrechercherresistancevirologiquetantoninishaim
QuandrechercherresistancevirologiquetantoninishaimQuandrechercherresistancevirologiquetantoninishaim
Quandrechercherresistancevirologiquetantoninishaim
 
Cohorteculpitacoilly
CohorteculpitacoillyCohorteculpitacoilly
Cohorteculpitacoilly
 
Quefairedevantlhyperferritinemiedusyndromemetabolique
QuefairedevantlhyperferritinemiedusyndromemetaboliqueQuefairedevantlhyperferritinemiedusyndromemetabolique
Quefairedevantlhyperferritinemiedusyndromemetabolique
 
Recommandationsafefpecvhcmbourliere
RecommandationsafefpecvhcmbourliereRecommandationsafefpecvhcmbourliere
Recommandationsafefpecvhcmbourliere
 
Nouvellestechniquesimageriecarcinomehepatocellulairelewin
NouvellestechniquesimageriecarcinomehepatocellulairelewinNouvellestechniquesimageriecarcinomehepatocellulairelewin
Nouvellestechniquesimageriecarcinomehepatocellulairelewin
 
Insuffisancehepatiqueaigue
InsuffisancehepatiqueaigueInsuffisancehepatiqueaigue
Insuffisancehepatiqueaigue
 
Nouveauteshepatologiedsamuel
NouveauteshepatologiedsamuelNouveauteshepatologiedsamuel
Nouveauteshepatologiedsamuel
 
Chirurgie : Quels indicateurs de qualité ? - Dr Gabriella Pittau
Chirurgie : Quels indicateurs de qualité ? - Dr Gabriella PittauChirurgie : Quels indicateurs de qualité ? - Dr Gabriella Pittau
Chirurgie : Quels indicateurs de qualité ? - Dr Gabriella Pittau
 
Les Nouvelles Règles de Transplantation Hépatique pour les patients ayant un ...
Les Nouvelles Règles de Transplantation Hépatique pour les patients ayant un ...Les Nouvelles Règles de Transplantation Hépatique pour les patients ayant un ...
Les Nouvelles Règles de Transplantation Hépatique pour les patients ayant un ...
 
La Transplantation hépatique pour les patients cirrhotiques graves (MELD > 35)
La Transplantation hépatique pour les patients cirrhotiques graves (MELD > 35)La Transplantation hépatique pour les patients cirrhotiques graves (MELD > 35)
La Transplantation hépatique pour les patients cirrhotiques graves (MELD > 35)
 
Traitements de l'Hépatite C Chronique en 2014 pour les patients cirrhotiques ...
Traitements de l'Hépatite C Chronique en 2014 pour les patients cirrhotiques ...Traitements de l'Hépatite C Chronique en 2014 pour les patients cirrhotiques ...
Traitements de l'Hépatite C Chronique en 2014 pour les patients cirrhotiques ...
 
Les Tests de Dépistage Rapide de l'Hépatite C : Quel impact sur la pratique m...
Les Tests de Dépistage Rapide de l'Hépatite C : Quel impact sur la pratique m...Les Tests de Dépistage Rapide de l'Hépatite C : Quel impact sur la pratique m...
Les Tests de Dépistage Rapide de l'Hépatite C : Quel impact sur la pratique m...
 
Hépatite B Chronique - Quelle stratégie pour éliminer l'Antigène HBs ?
Hépatite B Chronique - Quelle stratégie pour éliminer l'Antigène HBs ?Hépatite B Chronique - Quelle stratégie pour éliminer l'Antigène HBs ?
Hépatite B Chronique - Quelle stratégie pour éliminer l'Antigène HBs ?
 
Quels impact de l'hépatopathie sous jacente? - Dr Andrea Laurenzi
Quels impact de l'hépatopathie sous jacente? - Dr Andrea LaurenziQuels impact de l'hépatopathie sous jacente? - Dr Andrea Laurenzi
Quels impact de l'hépatopathie sous jacente? - Dr Andrea Laurenzi
 
Les moyens peropératoires de prévention de l'IHC - Dr Oriana Ciacio
Les moyens peropératoires de prévention de l'IHC - Dr Oriana CiacioLes moyens peropératoires de prévention de l'IHC - Dr Oriana Ciacio
Les moyens peropératoires de prévention de l'IHC - Dr Oriana Ciacio
 
Fréquence et impact de l'IHC post-opératoire dans les hépatectomies - Dr N...
Fréquence et impact de l'IHC post-opératoire dans les hépatectomies - Dr N...Fréquence et impact de l'IHC post-opératoire dans les hépatectomies - Dr N...
Fréquence et impact de l'IHC post-opératoire dans les hépatectomies - Dr N...
 
Radiofréquence combinée à la résection - Dr Gabriella pittau - Pr Antoni...
Radiofréquence combinée à la résection -  Dr Gabriella pittau - Pr Antoni...Radiofréquence combinée à la résection -  Dr Gabriella pittau - Pr Antoni...
Radiofréquence combinée à la résection - Dr Gabriella pittau - Pr Antoni...
 
Quoi de neuf dans les tumeurs primitives du foie ? - Dr Eric Vibert
Quoi de neuf dans les tumeurs primitives du foie ? - Dr Eric VibertQuoi de neuf dans les tumeurs primitives du foie ? - Dr Eric Vibert
Quoi de neuf dans les tumeurs primitives du foie ? - Dr Eric Vibert
 

Semelhante a Radiologieinterventionnellechctdebaere

SBRT versus Surgery in Early lung cancer : Debate
SBRT versus Surgery in Early lung cancer : DebateSBRT versus Surgery in Early lung cancer : Debate
SBRT versus Surgery in Early lung cancer : DebateRuchir Bhandari
 
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...Santam Chakraborty
 
Aurelia asco 20121
Aurelia asco 20121Aurelia asco 20121
Aurelia asco 20121lefein
 
Role of Post-op Radiotherapy in Head and Neck Cancers
Role of Post-op Radiotherapy in Head and Neck CancersRole of Post-op Radiotherapy in Head and Neck Cancers
Role of Post-op Radiotherapy in Head and Neck CancersAshutosh Mukherji
 
Treatment paradigms in the management of mbc bgicc 2014
Treatment paradigms in the management of mbc bgicc 2014 Treatment paradigms in the management of mbc bgicc 2014
Treatment paradigms in the management of mbc bgicc 2014 Mohamed Abdulla
 
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...European School of Oncology
 
Rectal cancer Preoperative Radiotherapy- Short vs long course
Rectal cancer Preoperative Radiotherapy- Short vs long courseRectal cancer Preoperative Radiotherapy- Short vs long course
Rectal cancer Preoperative Radiotherapy- Short vs long courseGaurav Kumar
 
Induction chemotherapy for locally advanced head and neck cancers
Induction chemotherapy for locally advanced head and neck cancers Induction chemotherapy for locally advanced head and neck cancers
Induction chemotherapy for locally advanced head and neck cancers spa718
 
C:\Documents And Settings\User\Desktop\Head And Neck
C:\Documents And Settings\User\Desktop\Head And NeckC:\Documents And Settings\User\Desktop\Head And Neck
C:\Documents And Settings\User\Desktop\Head And NeckGamal Abdul Hamid
 
ECCLU 2011 - B.I. Rini - Kidney cancer - First and further lines in mRCC
ECCLU 2011 - B.I. Rini - Kidney cancer - First and further lines in mRCCECCLU 2011 - B.I. Rini - Kidney cancer - First and further lines in mRCC
ECCLU 2011 - B.I. Rini - Kidney cancer - First and further lines in mRCCEuropean School of Oncology
 
NACT in Head and Neck cancer
NACT in Head and Neck cancerNACT in Head and Neck cancer
NACT in Head and Neck cancerAjay Manickam
 
Preoperative radiotherapy and surgery rectal cancers: optimal interval
Preoperative radiotherapy and surgery rectal cancers: optimal intervalPreoperative radiotherapy and surgery rectal cancers: optimal interval
Preoperative radiotherapy and surgery rectal cancers: optimal intervalGaurav Kumar
 
ECCLU 2011 - K. Fizazi - Testicular cancer - Treatment of advanced testicular...
ECCLU 2011 - K. Fizazi - Testicular cancer - Treatment of advanced testicular...ECCLU 2011 - K. Fizazi - Testicular cancer - Treatment of advanced testicular...
ECCLU 2011 - K. Fizazi - Testicular cancer - Treatment of advanced testicular...European School of Oncology
 
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)European School of Oncology
 
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)European School of Oncology
 
Radiation Therapy: Nutritional Strategies to Improve Outcomes
Radiation Therapy: Nutritional Strategies to Improve OutcomesRadiation Therapy: Nutritional Strategies to Improve Outcomes
Radiation Therapy: Nutritional Strategies to Improve OutcomesJeanne M Wallace PhD
 
SBRT in head and neck cancer
SBRT in  head and neck cancerSBRT in  head and neck cancer
SBRT in head and neck cancerDr Rushi Panchal
 
Exemestane Versus Tamoxifen
Exemestane Versus TamoxifenExemestane Versus Tamoxifen
Exemestane Versus Tamoxifenfondas vakalis
 
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...Mauricio Lema
 

Semelhante a Radiologieinterventionnellechctdebaere (20)

SBRT versus Surgery in Early lung cancer : Debate
SBRT versus Surgery in Early lung cancer : DebateSBRT versus Surgery in Early lung cancer : Debate
SBRT versus Surgery in Early lung cancer : Debate
 
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...
 
Aurelia asco 20121
Aurelia asco 20121Aurelia asco 20121
Aurelia asco 20121
 
Role of Post-op Radiotherapy in Head and Neck Cancers
Role of Post-op Radiotherapy in Head and Neck CancersRole of Post-op Radiotherapy in Head and Neck Cancers
Role of Post-op Radiotherapy in Head and Neck Cancers
 
Treatment paradigms in the management of mbc bgicc 2014
Treatment paradigms in the management of mbc bgicc 2014 Treatment paradigms in the management of mbc bgicc 2014
Treatment paradigms in the management of mbc bgicc 2014
 
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
 
Rectal cancer Preoperative Radiotherapy- Short vs long course
Rectal cancer Preoperative Radiotherapy- Short vs long courseRectal cancer Preoperative Radiotherapy- Short vs long course
Rectal cancer Preoperative Radiotherapy- Short vs long course
 
Induction chemotherapy for locally advanced head and neck cancers
Induction chemotherapy for locally advanced head and neck cancers Induction chemotherapy for locally advanced head and neck cancers
Induction chemotherapy for locally advanced head and neck cancers
 
C:\Documents And Settings\User\Desktop\Head And Neck
C:\Documents And Settings\User\Desktop\Head And NeckC:\Documents And Settings\User\Desktop\Head And Neck
C:\Documents And Settings\User\Desktop\Head And Neck
 
ECCLU 2011 - B.I. Rini - Kidney cancer - First and further lines in mRCC
ECCLU 2011 - B.I. Rini - Kidney cancer - First and further lines in mRCCECCLU 2011 - B.I. Rini - Kidney cancer - First and further lines in mRCC
ECCLU 2011 - B.I. Rini - Kidney cancer - First and further lines in mRCC
 
NACT in Head and Neck cancer
NACT in Head and Neck cancerNACT in Head and Neck cancer
NACT in Head and Neck cancer
 
Preoperative radiotherapy and surgery rectal cancers: optimal interval
Preoperative radiotherapy and surgery rectal cancers: optimal intervalPreoperative radiotherapy and surgery rectal cancers: optimal interval
Preoperative radiotherapy and surgery rectal cancers: optimal interval
 
Research Discussion
Research DiscussionResearch Discussion
Research Discussion
 
ECCLU 2011 - K. Fizazi - Testicular cancer - Treatment of advanced testicular...
ECCLU 2011 - K. Fizazi - Testicular cancer - Treatment of advanced testicular...ECCLU 2011 - K. Fizazi - Testicular cancer - Treatment of advanced testicular...
ECCLU 2011 - K. Fizazi - Testicular cancer - Treatment of advanced testicular...
 
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)
 
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)
 
Radiation Therapy: Nutritional Strategies to Improve Outcomes
Radiation Therapy: Nutritional Strategies to Improve OutcomesRadiation Therapy: Nutritional Strategies to Improve Outcomes
Radiation Therapy: Nutritional Strategies to Improve Outcomes
 
SBRT in head and neck cancer
SBRT in  head and neck cancerSBRT in  head and neck cancer
SBRT in head and neck cancer
 
Exemestane Versus Tamoxifen
Exemestane Versus TamoxifenExemestane Versus Tamoxifen
Exemestane Versus Tamoxifen
 
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
4-yr OS after 2nd-line Nivolumab, pooled analysis (based on Scott Antonia pre...
 

Mais de Centre Hepato-Biliaire / AP-HP Hopital Paul Brousse

Mais de Centre Hepato-Biliaire / AP-HP Hopital Paul Brousse (20)

Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
 
Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
 
Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
Situations difficiles en chirurgie biliaire : Présentations de trois cas clin...
 
Point de vue du chirurgien hépatique - M.A. Allard
Point de vue du chirurgien hépatique - M.A. AllardPoint de vue du chirurgien hépatique - M.A. Allard
Point de vue du chirurgien hépatique - M.A. Allard
 
Quoi de neuf dans les cancers primitifs du foie? - E. Vibert
Quoi de neuf dans les cancers primitifs du foie? - E. VibertQuoi de neuf dans les cancers primitifs du foie? - E. Vibert
Quoi de neuf dans les cancers primitifs du foie? - E. Vibert
 
Conférence du Président d'honneur : l'échinococcose alvéolaire - G. Mansson
Conférence du Président d'honneur : l'échinococcose alvéolaire - G. ManssonConférence du Président d'honneur : l'échinococcose alvéolaire - G. Mansson
Conférence du Président d'honneur : l'échinococcose alvéolaire - G. Mansson
 
Chirurgie guidée par la fluorescence - N. Golse
Chirurgie guidée par la fluorescence - N. GolseChirurgie guidée par la fluorescence - N. Golse
Chirurgie guidée par la fluorescence - N. Golse
 
Chirurgie de réduction tumorale des métastases hépatique non résécables de fa...
Chirurgie de réduction tumorale des métastases hépatique non résécables de fa...Chirurgie de réduction tumorale des métastases hépatique non résécables de fa...
Chirurgie de réduction tumorale des métastases hépatique non résécables de fa...
 
Déprivation veineuse portale et sus-hépatique. Indications actuelles et résul...
Déprivation veineuse portale et sus-hépatique. Indications actuelles et résul...Déprivation veineuse portale et sus-hépatique. Indications actuelles et résul...
Déprivation veineuse portale et sus-hépatique. Indications actuelles et résul...
 
Point de vue du chirurgien colorectal - S. Benoist
Point de vue du chirurgien colorectal - S. BenoistPoint de vue du chirurgien colorectal - S. Benoist
Point de vue du chirurgien colorectal - S. Benoist
 
Chirurgie hépatique sous perfusion hypothermique - D. Azoulay
Chirurgie hépatique sous perfusion hypothermique - D. AzoulayChirurgie hépatique sous perfusion hypothermique - D. Azoulay
Chirurgie hépatique sous perfusion hypothermique - D. Azoulay
 
Transplantation hépatique pour cancer: quelles tumeurs. A quelles conditions?...
Transplantation hépatique pour cancer: quelles tumeurs. A quelles conditions?...Transplantation hépatique pour cancer: quelles tumeurs. A quelles conditions?...
Transplantation hépatique pour cancer: quelles tumeurs. A quelles conditions?...
 
DPC par chirurgie mini-invasive: Où en sommes-nous? C. Salloum
DPC par chirurgie mini-invasive: Où en sommes-nous? C. SalloumDPC par chirurgie mini-invasive: Où en sommes-nous? C. Salloum
DPC par chirurgie mini-invasive: Où en sommes-nous? C. Salloum
 
Quoi de neuf dans les métastases hépatique?
Quoi de neuf dans les métastases hépatique?Quoi de neuf dans les métastases hépatique?
Quoi de neuf dans les métastases hépatique?
 
Destruction tumorale par écho-guidage optimisé - M.A. Allard
Destruction tumorale par écho-guidage optimisé - M.A. AllardDestruction tumorale par écho-guidage optimisé - M.A. Allard
Destruction tumorale par écho-guidage optimisé - M.A. Allard
 
Obésité et chirurgie HPB? Quels risques? Quelles recommandations? Quelle pris...
Obésité et chirurgie HPB? Quels risques? Quelles recommandations? Quelle pris...Obésité et chirurgie HPB? Quels risques? Quelles recommandations? Quelle pris...
Obésité et chirurgie HPB? Quels risques? Quelles recommandations? Quelle pris...
 
Quoi de neuf dans les cancers du pancréas? - G. Pittau
Quoi de neuf dans les cancers du pancréas? - G. PittauQuoi de neuf dans les cancers du pancréas? - G. Pittau
Quoi de neuf dans les cancers du pancréas? - G. Pittau
 
Quand l'intelligence artificielle s'invite au bloc opératoire Eric VIbert.pdf
Quand l'intelligence artificielle s'invite au bloc opératoire Eric VIbert.pdfQuand l'intelligence artificielle s'invite au bloc opératoire Eric VIbert.pdf
Quand l'intelligence artificielle s'invite au bloc opératoire Eric VIbert.pdf
 
Cas Clinique Sophie SAcleux.pdf
Cas Clinique Sophie SAcleux.pdfCas Clinique Sophie SAcleux.pdf
Cas Clinique Sophie SAcleux.pdf
 
En Recherche Jean Charles Duclos Vallée.pdf
En Recherche Jean Charles Duclos Vallée.pdfEn Recherche Jean Charles Duclos Vallée.pdf
En Recherche Jean Charles Duclos Vallée.pdf
 

Último

INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptKavitha Krishnan
 
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxThyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxRajendra Dev Bhatt
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyYves Sucaet
 
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...Genesis Institute of Pharmacy, Radhanagari.
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfMayuriGamit2
 
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Dr. Dheeraj Kumar
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptxRajendra Dev Bhatt
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKQuick MedTalk
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxSizan Thapa
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, PDr.Shalu Jain
 
Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxSizan Thapa
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......anupamdas2143
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxTina Purnat
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCEShubhadip Ghosh
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)pranavguleria2
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeQuick MedTalk
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptxnakera38
 
Reproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxReproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxVeereshDemashetti
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsPradnya Wadekar
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedSBL DIGITAL
 

Último (20)

INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
 
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptxThyroid function tests for MBBS, LAB. MED & BDS.pptx
Thyroid function tests for MBBS, LAB. MED & BDS.pptx
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathology
 
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
 
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, P
 
Ovarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptxOvarian tumors Lecture notes for MBBS.pptx
Ovarian tumors Lecture notes for MBBS.pptx
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......
 
Brief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptxBrief introduction to information ecosystem x public health.pptx
Brief introduction to information ecosystem x public health.pptx
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCE
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptx
 
Reproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxReproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptx
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractions
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limited
 

Radiologieinterventionnellechctdebaere

  • 1. Radiologie Interventionnelle & CHC Thierry de Baère Imagerie thérapeutique - Gustave Roussy - Villejuif Journée d’Hépatologie du Centre Hépato-Biliaire 12 juin 2015 - Paris
  • 2. J Hepatol 2012. 56; 908–943. JM. Llovet; R Lencioni; AM. Di Bisceglie; PR. Galle; JF Dufour; TF. Greten; E Raymond; T Roskams; T de Baere; Michel Ducreux; and Vincenzo Mazzaferro.
  • 3. J Hepatol 2012. 56; 908–943. JM. Llovet; R Lencioni; AM. Di Bisceglie; PR. Galle; JF Dufour; TF. Greten; E Raymond; T Roskams; T De Baere; Michel Ducreux; and Vincenzo Mazzaferro.
  • 4. % AP n=928 EU n=1113 LA n=90 USA n=563 Japan n=508 Overall N=3202 All LRTs 67.2 43.5 27.8 49.4 84.4 57.5 TACE 60.3 33.1 13.3 37.1 71.3 47.2 Conventional Lipiodol TACE * 90.2 59.2 83.3 40.7 82.3 73.9 DEB-TACE * 2.9 36.1 16.7 39.7 1.7 15.9 Ablation 15.5 20.2 17.8 12.6 50.0 22.2 Surgery 24.2 15.5 5.6 9.4 43.3 21.1 * For patients who received TACE: n=1511; AP=560, EU=368, LA=12, USA=209, Japan=362; AP, Asia-Pacific; LA, Latin America; LRTs, Loco-Regional Therapies Lencioni R et al. Int J Clin Pract 2014;68:609-617 GIDEON Pre-Sorafenib therapy in 3202 HCC (observation)
  • 5. Breen DJ,. Nat Rev Clin Oncol 2015;12:175-186 Ablation for Early-Stage HCC: Italy Japan Corea France
  • 6. Feng K et al. J Hepatol 2012;57:794-802Huang J et al. Ann Surg 2010;252:903-912 ● 230 patients, 94% Child A ● Single ≤ 5 cm, up to 3 ≤ 3 cm ● 168 patients, 49% Child A ● Up to 2 HCC tumors ≤ 4 cm Overall Survival Overall Survival months months p = 0.001 (log-rank test) p = 0.342 (log-rank test) Ablation vs. Resection : Randomized Trials
  • 7. Feng K et al. J Hepatol 2012;57:794-802Huang J et al. Ann Surg 2010;252:903-912 ● 230 patients, 94% Child A ● Single ≤ 5 cm, up to 3 ≤ 3 cm ● 168 patients, 49% Child A ● Up to 2 HCC tumors ≤ 4 cm Overall Survival Overall Survival months months p = 0.001 (log-rank test) p = 0.342 (log-rank test) Ablation vs. Resection : Randomized Trials
  • 8. "Very Early” (stage 0) vs "Early" (stage A) VS “Milan” Sasaki A et al. Cancer 2005;103:299-306 46% of patients with single HCC < 5 cm show microsatellites on histology Radiofrequency ablation is recommended in most instances as the main ablative therapy in tumours less than 5 cm due to a significantly better control of the disease (evidence 1iD; recommendation 1A) J Hepatol 2012. 56; 908–943. JM. Llovet; R Lencioni; AM. Di Bisceglie; PR. Galle; JF Dufour; TF. Greten; E Raymond; T Roskams; T de Baere; Michel Ducreux; and Vincenzo Mazzaferro. Milan criteria : X3 <3cm ; >5cm
  • 9. Pompili M et al. J Hepatol 2013;59:89-97 Tumor Recurrence Overall Survival
  • 10. Ablation in HCC : APASL Consensus Omata M et al. Hepatol Int 2010;4:439-474 LOCATION! T
  • 11. Omata M et al. Hepatol Int 2010;4:439-474 Ablation in HCC : APASL Consensus
  • 12. Forner et al. Lancet 2012;379:1245-1255 Ablation Ablation The Two Roles of Ablation in HCC Treatment: Updated BCLC Treatment Algorithm
  • 13. Focused Ultrasound Cryoablation Radiofrequency Ablation Irreversible Electroporation Laser AblationMicrowave Ablation
  • 14. Mazzaferro V, Lencioni R, Majno P. Semin Liver Dis 2014;34:415-426 Image-Guided Ablation of HCC: Evolving Methods and Technologies
  • 15. • Resection et ablation sont probablement équivalente pour les stade 0 et A (very early; early)  Complémentaire plus que compétitive : localisation • Pour les HCC < 5cm si candidat chirurgicaux limites  Rôle des nouvelles techniques d’ablation à définir , outil par outil  Traitement combiné (TACE+RF) • La difficultés est plus celle de la récidive à distance que de la récidive locale  Traitement préventif ! (STORM study) Ablation for Early-Stage HCC
  • 16. BCLC Staging and Treatment Strategy: Critical Considerations EASL-EORTC. J Hepatol 2012;56:908-943 - Eur J Cancer 2012;48:599-641
  • 17. BCLC Staging and Treatment Strategy: Critical Considerations EASL-EORTC. J Hepatol 2012;56:908-943 - Eur J Cancer 2012;48:599-641 ADVANCED STAGE: - ECOG PS 1-2 - Portal Vein Invasion - Extrahepatic Disease
  • 18. (Yau T. Gastroenterology 2014;146:1691–1700 )EVM : extrahe-patic or vascular invasion/metastasis 0 / 1 / 2 negative factor Tumor size: ≥ 5 cm Tumor number: ≥ 3 Intrahepatic vascular invasion
  • 19. (Yau T. Gastroenterology 2014;146:1691–1700 )
  • 20. • HKC identified subsets of BCLC B & 50% of BCLCC C more aggressive treatments than recommended by BCLC Such aggressive treatments Improved survival outcomes  hypothetical median OS: HKLC 16.6 months, BCLC 8.9 months) “The benefits of the HKLC system are clearly apparent when dealing with patients who have intermediate to advanced stage disease according to the BCLC”. “In a European cohort of HCC patients, the newly developed HKLC staging system does not seem to allow a better predictive value than the BCLC”. (Adhoute X. J Hepatol 2014) (Chapiro J. Nat Rev Gastroenterol Hepatol 2014;11:334-336)
  • 21. 177 patients randomized to DEB-TACE or c-TACE (med number of TACE = 2) • 89 DEB-TACE • 88 cTACE (Golfieri R. 2014 BJC; 111 : 255–264)
  • 22. CR OR DC Targeted Overall (Golfieri R. 2014 BJC; 111 : 255–264)
  • 23. (Golfieri R. 2014 BJC; 111 : 255–264)
  • 24. • Median TTP = 9 months in both arms • 1- and 2-year survival  86.2% and 56.8% after DEB-TACE  83.5% and 55.4% after cTACE (p=0.949). No difference in AE incidence and severity except post-TACE pain, more frequent and severe after cTACE (p=0.001). Pain did not affected the length of hospital stay and patient acceptance of additional TACEs (Golfieri R. 2014 BJC; 111 : 255–264)
  • 26. 67 DEB-TACE (53 patients) 100-300 μm (Group 1) lobar in 42 and selective in 7 cases 65 DEB-TACE (54 patients) 70-150 μm (Group 2) lobar in 60 and selective in 11 m-RECIST 1-2 months CR (%) PR (%) SD (%) PD (%) Group 1 19 2 67 12 Group 2 16 8 69 7 (Deipolyi AR, J Vasc Interv Radiol 2015; 26:516–522)
  • 27. BCLC Staging and Treatment Strategy: Critical Considerations EASL-EORTC. J Hepatol 2012;56:908-943 - Eur J Cancer 2012;48:599-641 Radioembolization - Sarra - Soramic - STOPP HCC
  • 28. A single-centre prospective study of 291 patients with HCC looked at long-term clinical outcomes with TheraSphere® Overall response rate according to WHO criteria was 42% TheraSphere® & HCC 29 Treatment response predicts survival benefit for BCLC A, B &C patients Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010;138(1):52–64.
  • 29. (Garlipp B, de Baere T, Seidensticker M. Hepatology 2014.59:1864-1873) 26 matched pairs PVE : 61.5 ± 39 % after 33 [24-56] days RE : 29 ± 28 % after 46 [27-79] days (p<0.001)
  • 31. (Peng ZW; JCO 2013. 31 426-432) HCC less than 7 cm (single), or X3 & <3cm TACE-RFA Vs RFA OS : (HR=0.525; 95% CI = 0.335-0.822; P = .002 ) DFS : (HR=0.575; 95% CI = 0.374-0.897; P = .009) OS : treatment allocation (HR=1.87), tum. Size 3cm (HR=1.73), and tum. number (HR=2.49) DFS : Treatment allocation (HR=1.67) and tum. Number (HR=1.97)
  • 32. HR: 0.797 95% Cl: 0.588, 1.08 P = 0.072 Sorafenib Median: 169 days 95% Cl: 166, 219 days Placebo Median: 166 days 95% Cl: 113, 168 days PrimaryEndpoint Sorafenib 400mg bid Matching Placebo R A N D O M I Z E 1 3 5 7 9 11 13 15 17 19 TACE (optional) Cycle no (=4 weeks) n=154 n=153 SPACE Trial
  • 33. PRODIGE 16 - ESSAI FFCD 0905 ESSAI RANDOMISE EN DOUBLE AVEUGLE DE PHASE II-III EVALUANT LA CHIMIOEMBOLISATION COMBINEE AU SUNITINIB OU A UN PLACEBO CHEZ DES PATIENTS ATTEINTS DE CARCINOME HEPATOCELLULAIRE (SATURNE) DEB - TACE with sunitinib 37.5 mg/d orally 4 weeks out of 6 started 7-15 days before TACE for one year vs placebo. Primary end-point : specific safety of the TACE-sunitinib combination (severe bleeding, liver failure , …) Secondary end-points : general safety, progression-free survival (PFS), Overall Survival (OS), quality of life. May 2011 to May 2014 : 78 patients were randomized (39 in each arm) median age 66 years [IQR (60-70)]. Bilobar HCC : 41 / 70 patients The median number of cycles was 3 [IQR : 2 :5 ] in arm A and 5 [IQR : 4 :7 ] in arm B .No bleeding complication; 1liver failure (PT = 40%) armA, & 2 liver failure in arm B (PT=42%, ,encephalopathy). Sunitinib dose was reduced to 25 mg/d as a result of toxicity for 19 pts (48.7%) in arm A. 6 patients are still under treatment (3 in each arm). The main grades 3-4 toxicities were: thrombocytopenia (28.2% vs. 2.6% in placebo arm), neutropenia (28.2% vs. none), asthenia (20.5% vs. 5.3%), diarrhea (5.1% vs. none) respectively in arm A and B. The median PFS in arm A was 8.8 [95%CI 5.8 -12] months, and 6.3 [95%CI 4.2 - 9.0 ] months in arm B. Conclusion This study indicated a modest and manageable toxicity of sunitinib when combined with TACE. Regarding efficacy endpoints (PFS and OS) we are waiting for more mature data as 6 patients are still under treatment.
  • 34. RFA plus Sorafenib vs RFA Alone in RCC Hakimé et al, Radiology 2007 4-time increase in ablation volume
  • 35. 125 HCC received TACE group A (n = 61) : TACE + As2O3 at 10 mg/d for 4 courses (21 days per course) group B (n = 64) : TACE alone
  • 36. 125 HCC received TACE group A (n = 61) : TACE + As2O3 at 10 mg/d for 4 courses (21 days per course) group B (n = 64) : TACE alone
  • 37. J Vasc Interv Radiol 2014; 25:379–387
  • 38. % EU n=1113 Overall N=3202 All LRTs 43.5 57.5 TACE 33.1 47.2 Conventional Lipiodol TACE * 59.2 73.9 DEB-TACE * 36.1 15.9 Ablation 20.2 22.2 Surgery 15.5 21.1 Conclusion DOSISPHERES-01 Y-90 GLASS MICROSPHERES FOR HCC :OPTIMIZED DOSIMETRY vs STANDARD DOSIMETRY STOPP HCC Y-90 GLASS MICROSPHERES FOR HCC PRIOR TO SORAFENIB THERAPY vs STANDARD DOSIMETRY Sunitinib loaded beads Lipiodol ready to inject emulsion